- Home
- XP vs CORT Comparison
XP vs CORT Comparison
Compare XP & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XP | CORT |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.6B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | XP | CORT |
|---|---|---|
| Price | $16.13 | $37.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $22.80 | ★ $111.00 |
| AVG Volume (30 Days) | ★ 6.2M | 2.4M |
| Earning Date | 02-17-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | ★ 18.53 | N/A |
| EPS | ★ 1.76 | 0.87 |
| Revenue | ★ $3,229,174,949.00 | $741,172,000.00 |
| Revenue This Year | $17.10 | $23.96 |
| Revenue Next Year | $12.69 | $43.40 |
| P/E Ratio | ★ $9.17 | $43.73 |
| Revenue Growth | 8.33 | ★ 17.92 |
| 52 Week Low | $10.82 | $32.99 |
| 52 Week High | $20.64 | $117.33 |
Technical Indicators
Market Signals| Indicator | XP | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 37.51 | 17.53 |
| Support Level | $16.25 | $32.99 |
| Resistance Level | $16.69 | $85.34 |
| Average True Range (ATR) | 0.43 | 4.07 |
| MACD | -0.02 | -5.26 |
| Stochastic Oscillator | 20.68 | 8.23 |
Price Performance
Historical ComparisonAbout XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.